MRK Stock Forecast: Science-Driven Growth with Blockbuster Potential

Milana LedovaThis MRK Stock Forecast article was written by Milana Ledova – Financial Analyst at I Know First

Highlights

  • Merck is doubling down on its core strengths: oncology, vaccines, and animal health.
  • Key pipeline assets and blockbuster Keytruda will fuel near-term and long-term earnings.
  • Valuation remains compelling versus other Big Pharma names, particularly given Merck’s innovation pipeline.

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here